Today: 30 January 2026
Subscribe
Browse Category

NASDAQ:RGNX News 29 January 2026

Denali Therapeutics stock price rises as FDA freezes rival Regenxbio’s Hunter syndrome gene therapy trials

Denali Therapeutics stock price rises as FDA freezes rival Regenxbio’s Hunter syndrome gene therapy trials

New York, Jan 29, 2026, 15:20 EST — Regular session • Denali Therapeutics shares climbed in afternoon trading, gaining ground while the broader biotech sector remained flat.• Attention intensified following the FDA’s decision to halt Regenxbio’s rare-disease gene therapy trials.• Investors are now zeroed in on Denali’s FDA timeline for its Hunter syndrome treatment and the data update expected in…
29 January 2026
·····

Stock Market Today

  • Jim Cramer Highlights Price-to-Earnings Drop Behind Software Stocks' Slide
    January 29, 2026, 7:26 PM EST. Jim Cramer said software stocks like ServiceNow are struggling as their price-to-earnings (P/E) multiples shrink, reflecting investor uncertainty about future profits amid AI disruption concerns. P/E multiple shows how much investors pay for each dollar of future earnings. Despite strong results and buybacks, ServiceNow's shares dropped nearly 10%, down about 49% year-over-year versus an 11% decline in a software ETF and a 15% gain in the S&P 500. Cramer called the P/E decline a "brutal vote" against confidence in these companies' earnings trajectory, though he still sees long-term potential once multiples stabilize.
Go toTop